Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Journal of medical economics·2026
Same author

[Translated article] Making research accessible, breaking down barriers: the new frontier of clinical trials.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same author

Making research accessible, breaking down barriers: The new frontier of clinical trials.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2026
Same author

Economic impact of lung cancer clinical trials: Assessing cost savings in medication and testing.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Standardizing hospital pharmacy practice in home hospitalization: results from a multidisciplinary Delphi consensus in Spain.

Frontiers in public health·2025
Same author

[Translated article] Knowledge, perception and predisposition to implement the MAPEX strategy in hospital pharmacy residents in Spain. FIRMAPEX project.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2025

Related Experiment Video

Updated: Jun 23, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Real-World Experience at

Miguel Angel Rodríguez Sagrado1, Javier Alvarez Criado2, Ainhoa Elisa Arenaza Peña3

  • 1Pharmacy Service, Hospital Universitario Ramón y Cajal, Madrid, Spain. mrsagrado@salud.madrid.org.

Targeted Oncology
|January 24, 2025
PubMed
Summary

Niraparib maintenance therapy demonstrates real-world effectiveness and tolerability in platinum-sensitive recurrent ovarian cancer (OC). This study confirms its activity and highlights potential economic savings for patients with OC.

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

Related Experiment Videos

Last Updated: Jun 23, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy shows promise in clinical trials for ovarian cancer (OC).
  • Real-world data is needed to confirm PARPi benefits in a broader patient population.
  • Platinum-sensitive recurrent OC requires effective maintenance strategies.

Purpose of the Study:

  • To evaluate the real-world effectiveness and tolerability of niraparib maintenance in platinum-sensitive recurrent OC.
  • To assess safety, progression-free survival (PFS), and overall survival (OS) with niraparib.
  • To determine economic savings associated with an individualized starting dose (ISD) strategy.

Main Methods:

  • Retrospective observational study of 217 patients with platinum-sensitive relapsed high-grade serous OC receiving niraparib maintenance.
  • Data collected on patient characteristics, niraparib dosing, effectiveness (PFS, OS), and safety.
  • Analysis included comparison of ISD strategy versus standard dosing and assessment of prognostic factors.

Main Results:

  • Median PFS was 10.8 months; effectiveness varied by prior treatment lines, response, BRCA status, and FIGO stage.
  • Dose adjustments were needed in 56% of patients, primarily for hematologic toxicities.
  • Niraparib maintenance demonstrated tolerability and activity, with observed economic savings.

Conclusions:

  • Niraparib maintenance is well-tolerated and effective in a real-world setting for platinum-sensitive recurrent OC.
  • Patient-specific factors significantly influence treatment effectiveness.
  • The study supports niraparib's role in managing recurrent OC and suggests economic benefits.